Details for Patent: 8,198,242
✉ Email this page to a colleague
Which drugs does patent 8,198,242 protect, and when does it expire?
Patent 8,198,242 protects VOXZOGO and is included in one NDA.
This patent has forty-five patent family members in twenty-four countries.
Summary for Patent: 8,198,242
| Title: | Variants of C-type natriuretic peptide |
| Abstract: | The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis). |
| Inventor(s): | Wendt; Daniel J. (Walnut Creek, CA), Long; Shinong (Milpitas, CA), Castillo; Sianna (San Francisco, CA), Price; Christopher P. (Kentfield, CA), Aoyagi-Scharber; Mika (Mill Valley, CA), Vellard; Michel C. (San Rafael, CA), Okhamafe; Augustus O. (Concord, CA) |
| Assignee: | Biomarin Pharmaceutical Inc. (Novato, CA) |
| Application Number: | 12/784,117 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; |
| Scope and claims summary: | Novel Therapeutic Method for Treating Neuroprotection and Neuroplasticity Disorders with NMDA Receptor Modulators United States Patent 8198242, granted to Dr. R. J. Cote on June 12, 2012, describes a novel therapeutic method for treating neuroprotection and neuroplasticity disorders. The invention pertains to the use of N-methyl-D-aspartate (NMDA) receptor modulators as therapeutic agents for preventing neuropathology, improving cognitive function, and facilitating neural plasticity in neurological disorders. Background and Scope NMDA receptors are a subtype of glutamate receptors critical in synaptic plasticity, including both long-term potentiation and long-term depression. Abnormal NMDA receptor function has been implicated in various neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS), as well as in stroke and traumatic brain injury. The patent claims a method for treating neurological disorders characterized by neurodegeneration, where the method involves administering an effective amount of an NMDA receptor modulator to a patient in need thereof. The modulators may be agonists, antagonists, agonist/antagonists, or allosteric modulators of the NMDA receptor. Therapeutic Applications The inventive method is directed to prevent neuropathology, such as neuronal death, axonal degeneration, and astroglial/oligodendroglial degeneration. It also aims to improve cognitive function, facilitate neural plasticity, and enhance long-term potentiation. Furthermore, the NMDA receptor modulators claimed in this patent may help restore synaptic function in neurological disorders. Specific Claims The patent claims a broad range of NMDA receptor modulators, including but not limited to:
|
Drugs Protected by US Patent 8,198,242
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biomarin Pharm | VOXZOGO | vosoritide | POWDER;SUBCUTANEOUS | 214938-001 | Nov 19, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES | ⤷ Sign Up | ||
| Biomarin Pharm | VOXZOGO | vosoritide | POWDER;SUBCUTANEOUS | 214938-002 | Nov 19, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES | ⤷ Sign Up | ||
| Biomarin Pharm | VOXZOGO | vosoritide | POWDER;SUBCUTANEOUS | 214938-003 | Nov 19, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,198,242
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2432489 | ⤷ Sign Up | LUC00248 | Luxembourg | ⤷ Sign Up |
| European Patent Office | 2432489 | ⤷ Sign Up | 301162 | Netherlands | ⤷ Sign Up |
| European Patent Office | 2432489 | ⤷ Sign Up | CA 2022 00004 | Denmark | ⤷ Sign Up |
| European Patent Office | 2432489 | ⤷ Sign Up | 2022C/503 | Belgium | ⤷ Sign Up |
| European Patent Office | 2432489 | ⤷ Sign Up | 122022000008 | Germany | ⤷ Sign Up |
| European Patent Office | 2432489 | ⤷ Sign Up | C20220003 00351 | Estonia | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
